Skip to Content

Generic Sivextro Availability

Sivextro is a brand name of tedizolid, approved by the FDA in the following formulation(s):

SIVEXTRO (tedizolid phosphate - powder;iv (infusion))

  • Manufacturer: CUBIST PHARMS LLC
    Approval date: June 20, 2014
    Strength(s): 200MG/VIAL [RLD]

SIVEXTRO (tedizolid phosphate - tablet;oral)

  • Manufacturer: CUBIST PHARMS LLC
    Approval date: June 20, 2014
    Strength(s): 200MG [RLD]

Has a generic version of Sivextro been approved?

No. There is currently no therapeutically equivalent version of Sivextro available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sivextro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Oxazolidinone derivatives
    Patent 7,816,379
    Issued: October 19, 2010
    Inventor(s): Rhee; Jae Keol & Im; Weon Bin & Cho; Chong Hwan & Choi; Sung Hak & Lee; Tae Ho
    Assignee(s): Dong-A Pharm. Co., Ltd.
    The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.
    Patent expiration dates:
    • February 23, 2028
      ✓ 
      Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Oxazolidinone derivatives
    Patent 8,420,676
    Issued: April 16, 2013
    Assignee(s): Dong-A Pharmaceuticals Co. Ltd.
    The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as, Staphylococci, Enterococci and Streptococci anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.
    Patent expiration dates:
    • February 23, 2028
      ✓ 
      Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
    Patent 8,426,389
    Issued: April 23, 2013
    Assignee(s): Trius Therapeutics, Inc.
    A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi , anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the crystalline form may be used in antibiotics.
    Patent expiration dates:
    • December 31, 2030
      ✓ 
      Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • June 20, 2019 - NEW CHEMICAL ENTITY
    • June 20, 2024 - GENERATING ANTIBIOTIC INCENTIVES NOW

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide